Need help finding what you are looking for?
Contact Us
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1933368
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1933368
Canine Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
PUBLISHED:
PAGES: 167 Pages
DELIVERY TIME: Inquiry
SELECT AN OPTION
Growth Factors of canine vaccines Market
The global canine vaccines market was valued at USD 1.95 billion in 2025 and is projected to grow to USD 2.05 billion in 2026, eventually reaching USD 3.64 billion by 2034, reflecting a CAGR of 7.42% during the forecast period. North America dominated the market in 2025 with a 44.85% share, owing to advanced veterinary healthcare infrastructure, rising pet ownership, and strong awareness regarding canine disease prevention. The market is witnessing robust growth driven by the humanization of pets, increasing disposable income, and the growing adoption of preventive healthcare for dogs.
Leading companies in the market include Zoetis Services LLC, Merck & Co., Inc., Elanco, Boehringer Ingelheim International GmbH, Virbac, Ceva, Bioveta a.s., Indian Immunologicals Ltd., HIPRA, and Brilliant Bio Pharma, offering innovative vaccination solutions and expanding footprints globally. Recent research developments, such as Yale School of Medicine's cancer vaccine targeting canine EGFR/HER2 proteins in March 2024, underscore the increasing focus on novel vaccines for canine health.
Market Dynamics
Drivers: Rising pet ownership worldwide and growing willingness among pet owners to invest in advanced healthcare for dogs are primary drivers of market growth. In September 2022, the Global Animal Health Association reported around 85 million pet dogs in U.S. households, highlighting the potential for vaccine adoption. Increasing awareness about preventing diseases such as kennel cough, Lyme disease, and canine influenza further accelerates market growth.
Restraints: Vaccine hesitancy among dog owners poses a significant challenge. Concerns over vaccine safety, side effects, and the perceived necessity of routine vaccination reduce adoption rates. As per GAVI in January 2025, 4% of dogs and 12% of cats remained unvaccinated against rabies, reflecting ongoing resistance and market limitations.
Opportunities: Development and approval of novel combination vaccines offer broad-spectrum protection against multiple diseases. In July 2025, Elanco received USDA approval for TruCan Ultra CIV H3N2/H3N8, a canine influenza combination vaccine using PureFil technology. Such innovations improve convenience, reduce adverse reactions, and enhance comprehensive disease prevention.
Challenges: Decline in veterinary visits and shortage of skilled professionals affect market growth. Between 2021-2023, client visits fell by 2.7%, while a shortage of approximately 15,000 veterinarians exists globally compared to projected needs by 2030. These factors hamper vaccine adoption and present challenges for industry stakeholders.
Market Trends
The development of easy-to-administer vaccines, such as intranasal vaccines, is a growing trend. These vaccines reduce stress for pets and enable quick immune responses without specialized personnel. For instance, in March 2025, Zoetis Services LLC launched Vanguard B Intranasal vaccine, targeting Bordetella bronchiseptica (kennel cough), reflecting a shift toward efficient, user-friendly vaccination solutions.
Segmentation Analysis
By Technology:
- Inactivated vaccines dominate due to strong safety profiles and practitioner acceptance. For example, in November 2024, Boehringer Ingelheim launched Eurican L4, protecting against leptospirosis.
- Live attenuated vaccines offer long-lasting immunity with fewer boosters. Merck's NOBIVAC CANINE 1-DAPPv combines protection against multiple viruses.
- Recombinant and other vaccines are growing due to safer, precise targeting.
By Disease Type:
- Canine influenza leads due to rising cases and new approvals, e.g., NOBIVAC NXT Canine Flu H3N2 in June 2024.
- Rabies remains significant, with global vaccination programs. In Bangladesh, 2.25 million doses were used to vaccinate 81.57% of stray dogs by June 2022.
- Lyme disease and leptospirosis are also growing, driven by increasing disease incidence and preventive care adoption.
By Route of Administration:
- Oral vaccines dominate due to ease of use for veterinarians and pets. Merck launched Nobivac Intra-Trac Oral BbPi in September 2022.
- Intranasal vaccines are expanding, providing convenience and reduced stress.
- Parenteral vaccines maintain significant market presence due to government-supported vaccination programs.
By Distribution Channel:
- Veterinary hospitals lead due to advanced facilities and pet owner preference. For instance, Royal Veterinary College's Beaumont Sainsbury Animal Hospital earned Dog Friendly Clinic accreditation in August 2025.
- Veterinary clinics are growing with AI-assisted solutions like VetRec partnered with Bond Vet in January 2025.
- Pharmacies & drug stores and other channels grow moderately.
Regional Outlook
- North America: Valued at USD 0.88 billion in 2025, led by the U.S. with advanced healthcare and government support.
- Europe: Significant growth, driven by increasing pet ownership; in the U.K., 28% of adults own dogs (PDSA 2024).
- Asia Pacific: Expected to witness the highest CAGR, supported by emerging markets and strategic expansions, e.g., Bioveta partnered with Vetina Healthcare in September 2024 in India.
- Latin America & Middle East & Africa: Moderate growth, propelled by government vaccination initiatives, e.g., Boeringer Ingelheim's rabies drive in Kenya, December 2024.
Competitive Landscape
The market is semi-fragmented, with leading companies focusing on product launches, R&D, and strategic collaborations. Key players include Zoetis, Merck, Elanco, Boehringer Ingelheim, Virbac, Ceva, Bioveta, IIL, HIPRA, and Brilliant Bio Pharma. Recent industry developments include:
- August 2025: Bioveta launched Biocan vaccines in Venezuela.
- November 2024: Ceva established a new vaccine facility in Hungary.
- July 2024: IIL conducted nationwide anti-rabies vaccination drives in India.
Conclusion
The global canine vaccines market is expected to grow from USD 1.95 billion in 2025 to USD 2.05 billion in 2026, reaching USD 3.64 billion by 2034 at a CAGR of 7.42%. Growth is driven by rising pet ownership, humanization of pets, preventive healthcare adoption, and government initiatives. North America dominates, while Asia Pacific exhibits the highest CAGR. Despite challenges such as vaccine hesitancy and professional shortages, innovations in combination vaccines, intranasal delivery, and strategic expansions are set to sustain market growth over the forecast period.
Segmentation By Technology
- Inactivated
- Live Attenuated
- Recombinant
- Others
By Disease Type
- Canine Influenza
- Lyme Disease
- Rabies
- Leptospirosis
- Others
By Route of Administration
- Oral
- Parenteral
- Intranasal
By Distribution Channel
- Veterinary Hospitals
- Veterinary Clinics
- Pharmacies & Drug Stores
- Others
By Region
- North America (By Technology, By Disease Type, By Route of Administration, By Distribution Channel, By Country/ Sub-Region)
- U.S.
- Canada
- Europe (By Technology, By Disease Type, By Route of Administration, By Distribution Channel, By Country/ Sub-Region)
- U.K.
- Germany
- France
- Italy
- Spain
- Scandinavia
- Rest of Europe
- Asia Pacific (By Technology, By Disease Type, By Route of Administration, By Distribution Channel, By Country/ Sub-Region)
- Japan
- China
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
- Latin America (By Technology, By Disease Type, By Route of Administration, By Distribution Channel, By Country/ Sub-Region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa (By Technology, By Disease Type, By Route of Administration, By Distribution Channel, By Country/ Sub-Region)
- GCC
- South Africa
- Rest of the Middle East & Africa
Product Code: FBI113897
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Overview of Canine Diseases by Key Countries, By Key Countries/ Region, 2025
- 4.2. Regulatory Scenario by Key Countries/ Region, 2025
- 4.3. Overview of Vaccination for Canine Diseases
- 4.4. New Technology Launches, By Key Players
- 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
5. Global Canine Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Technology
- 5.1.1. Inactivated
- 5.1.2. Live Attenuated
- 5.1.3. Recombinant
- 5.1.4. Others
- 5.2. Market Analysis, Insights and Forecast - By Disease Type
- 5.2.1. Canine Influenza
- 5.2.2. Lyme Disease
- 5.2.3. Rabies
- 5.2.4. Leptospirosis
- 5.2.5. Others
- 5.3. Market Analysis, Insights and Forecast - By Route of Administration
- 5.3.1. Oral
- 5.3.2. Parenteral
- 5.3.3. Intranasal
- 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.4.1. Veterinary Hospitals
- 5.4.2. Veterinary Clinics
- 5.4.3. Pharmacies & Drug Stores
- 5.4.4. Others
- 5.5. Market Analysis, Insights and Forecast - Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America
- 5.5.5. Middle East & Africa
6. North America Canine Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Technology
- 6.1.1. Inactivated
- 6.1.2. Live Attenuated
- 6.1.3. Recombinant
- 6.1.4. Others
- 6.2. Market Analysis, Insights and Forecast - By Disease Type
- 6.2.1. Canine Influenza
- 6.2.2. Lyme Disease
- 6.2.3. Rabies
- 6.2.4. Leptospirosis
- 6.2.5. Others
- 6.3. Market Analysis, Insights and Forecast - By Route of Administration
- 6.3.1. Oral
- 6.3.2. Parenteral
- 6.3.3. Intranasal
- 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.4.1. Veterinary Hospitals
- 6.4.2. Veterinary Clinics
- 6.4.3. Pharmacies & Drug Stores
- 6.4.4. Others
- 6.5. Market Analysis, Insights and Forecast - By Country
- 6.5.1. U.S.
- 6.5.2. Canada
7. Europe Canine Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Technology
- 7.1.1. Inactivated
- 7.1.2. Live Attenuated
- 7.1.3. Recombinant
- 7.1.4. Others
- 7.2. Market Analysis, Insights and Forecast - By Disease Type
- 7.2.1. Canine Influenza
- 7.2.2. Lyme Disease
- 7.2.3. Rabies
- 7.2.4. Leptospirosis
- 7.2.5. Others
- 7.3. Market Analysis, Insights and Forecast - By Route of Administration
- 7.3.1. Oral
- 7.3.2. Parenteral
- 7.3.3. Intranasal
- 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.4.1. Veterinary Hospitals
- 7.4.2. Veterinary Clinics
- 7.4.3. Pharmacies & Drug Stores
- 7.4.4. Others
- 7.5. Market Analysis, Insights and Forecast - By Technology
- 7.5.1. Inactivated
- 7.5.2. Live Attenuated
- 7.5.3. Recombinant
- 7.5.4. Others
- 7.6. Market Analysis, Insights and Forecast - By Disease Type
- 7.6.1. Canine Influenza
- 7.6.2. Lyme Disease
- 7.6.3. Rabies
- 7.6.4. Leptospirosis
- 7.6.5. Others
- 7.7. Market Analysis, Insights and Forecast - By Route of Administration
- 7.7.1. Oral
- 7.7.2. Parenteral
- 7.7.3. Intranasal
- 7.8. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.8.1. Veterinary Hospitals
- 7.8.2. Veterinary Clinics
- 7.8.3. Pharmacies & Drug Stores
- 7.8.4. Others
- 7.9. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 7.9.1. Germany
- 7.9.2. U.K.
- 7.9.3. France
- 7.9.4. Italy
- 7.9.5. Spain
- 7.9.6. Scandinavia
- 7.9.7. Rest of Europe
8. Asia Pacific Canine Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Technology
- 8.1.1. Inactivated
- 8.1.2. Live Attenuated
- 8.1.3. Recombinant
- 8.1.4. Others
- 8.2. Market Analysis, Insights and Forecast - By Disease Type
- 8.2.1. Canine Influenza
- 8.2.2. Lyme Disease
- 8.2.3. Rabies
- 8.2.4. Leptospirosis
- 8.2.5. Others
- 8.3. Market Analysis, Insights and Forecast - By Route of Administration
- 8.3.1. Oral
- 8.3.2. Parenteral
- 8.3.3. Intranasal
- 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.4.1. Veterinary Hospitals
- 8.4.2. Veterinary Clinics
- 8.4.3. Pharmacies & Drug Stores
- 8.4.4. Others
- 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 8.5.1. China
- 8.5.2. Japan
- 8.5.3. India
- 8.5.4. Australia
- 8.5.5. Southeast Asia
- 8.5.6. Rest of Asia Pacific
9. Latin America Canine Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Technology
- 9.1.1. Inactivated
- 9.1.2. Live Attenuated
- 9.1.3. Recombinant
- 9.1.4. Others
- 9.2. Market Analysis, Insights and Forecast - By Disease Type
- 9.2.1. Canine Influenza
- 9.2.2. Lyme Disease
- 9.2.3. Rabies
- 9.2.4. Leptospirosis
- 9.2.5. Others
- 9.3. Market Analysis, Insights and Forecast - By Route of Administration
- 9.3.1. Oral
- 9.3.2. Parenteral
- 9.3.3. Intranasal
- 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.4.1. Veterinary Hospitals
- 9.4.2. Veterinary Clinics
- 9.4.3. Pharmacies & Drug Stores
- 9.4.4. Others
- 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 9.5.1. Brazil
- 9.5.2. Mexico
- 9.5.3. Rest of Latin America
10. Middle East & Africa Canine Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast - By Technology
- 10.1.1. Inactivated
- 10.1.2. Live Attenuated
- 10.1.3. Recombinant
- 10.1.4. Others
- 10.2. Market Analysis, Insights and Forecast - By Disease Type
- 10.2.1. Canine Influenza
- 10.2.2. Lyme Disease
- 10.2.3. Rabies
- 10.2.4. Leptospirosis
- 10.2.5. Others
- 10.3. Market Analysis, Insights and Forecast - By Route of Administration
- 10.3.1. Oral
- 10.3.2. Parenteral
- 10.3.3. Intranasal
- 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 10.4.1. Veterinary Hospitals
- 10.4.2. Veterinary Clinics
- 10.4.3. Pharmacies & Drug Stores
- 10.4.4. Others
- 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 10.5.1. GCC
- 10.5.2. South Africa
- 10.5.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2025)
- 11.2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
- 11.2.1. Elanco
- 11.2.2. Boehringer Ingelheim International GmbH
- 11.2.3. Virbac
- 11.2.4. Merck & Co., Inc.
- 11.2.5. Zoetis Services LLC
- 11.2.6. Ceva
- 11.2.7. Bioveta, a.s.
- 11.2.8. Indian Immunologicals Ltd.
- 11.2.9. HIPRA
- 11.2.10. Brilliant Bio Pharma (India)
Product Code: FBI113897
List of Tables
- Table 1: Global Canine Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
- Table 2: Global Canine Vaccines Market Revenue (USD billion) Forecast, by Disease Type, 2021-2034
- Table 3: Global Canine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 4: Global Canine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 5: Global Canine Vaccines Market Revenue (USD billion) Forecast, by Region, 2021-2034
- Table 6: North America Canine Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
- Table 7: North America Canine Vaccines Market Revenue (USD billion) Forecast, by Disease Type, 2021-2034
- Table 8: North America Canine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 9: North America Canine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 10: North America Canine Vaccines Market Revenue (USD billion) Forecast, By Country, 2021-2034
- Table 11: Europe Canine Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
- Table 12: Europe Canine Vaccines Market Revenue (USD billion) Forecast, by Disease Type, 2021-2034
- Table 13: Europe Canine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 14: Europe Canine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 15: Europe Canine Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 16: Asia Pacific Canine Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
- Table 17: Asia Pacific Canine Vaccines Market Revenue (USD billion) Forecast, by Disease Type, 2021-2034
- Table 18: Asia Pacific Canine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 19: Asia Pacific Canine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 20: Asia Pacific Canine Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 21: Latin America Canine Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
- Table 22: Latin America Canine Vaccines Market Revenue (USD billion) Forecast, by Disease Type, 2021-2034
- Table 23: Latin America Canine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 24: Latin America Canine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 25: Latin America Canine Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 26: Middle East & Africa Canine Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
- Table 27: Middle East & Africa Canine Vaccines Market Revenue (USD billion) Forecast, by Disease Type, 2021-2034
- Table 28: Middle East & Africa Canine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 29: Middle East & Africa Canine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 30: Middle East & Africa Canine Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
List of Figures
- Figure 1: Global Canine Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
- Figure 2: Global Canine Vaccines Market Value Share (%), by Technology, 2025 & 2034
- Figure 3: Global Canine Vaccines Market Value Share (%), by Disease Type, 2025 & 2034
- Figure 4: Global Canine Vaccines Market Value Share (%), by Route of Administration, 2025 & 2034
- Figure 5: Global Canine Vaccines Market Value Share (%), by Distribution Channel, 2025 & 2034
- Figure 6: Global Canine Vaccines Market Value Share (%), by Region, 2025 & 2034
- Figure 7: North America Canine Vaccines Market Value (USD billion), by Technology, 2025 & 2034
- Figure 8: North America Canine Vaccines Market Value Share (%), by Technology, 2025
- Figure 9: North America Canine Vaccines Market Value (USD billion), by Disease Type, 2025 & 2034
- Figure 10: North America Canine Vaccines Market Value Share (%), by Disease Type, 2025
- Figure 11: North America Canine Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 12: North America Canine Vaccines Market Value Share (%), by Route of Administration, 2025
- Figure 13: North America Canine Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 14: North America Canine Vaccines Market Value Share (%), by Distribution Channel, 2025
- Figure 15: North America Canine Vaccines Market Value (USD billion), By Country, 2025 & 2034
- Figure 16: North America Canine Vaccines Market Value Share (%), By Country, 2025
- Figure 17: Europe Canine Vaccines Market Value (USD billion), by Technology, 2025 & 2034
- Figure 18: Europe Canine Vaccines Market Value Share (%), by Technology, 2025
- Figure 19: Europe Canine Vaccines Market Value (USD billion), by Disease Type, 2025 & 2034
- Figure 20: Europe Canine Vaccines Market Value Share (%), by Disease Type, 2025
- Figure 21: Europe Canine Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 22: Europe Canine Vaccines Market Value Share (%), by Route of Administration, 2025
- Figure 23: Europe Canine Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 24: Europe Canine Vaccines Market Value Share (%), by Distribution Channel, 2025
- Figure 25: Europe Canine Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 26: Europe Canine Vaccines Market Value Share (%), By Country/ Sub-region, 2025
- Figure 27: Asia Pacific Canine Vaccines Market Value (USD billion), by Technology, 2025 & 2034
- Figure 28: Asia Pacific Canine Vaccines Market Value Share (%), by Technology, 2025
- Figure 29: Asia Pacific Canine Vaccines Market Value (USD billion), by Disease Type, 2025 & 2034
- Figure 30: Asia Pacific Canine Vaccines Market Value Share (%), by Disease Type, 2025
- Figure 31: Asia Pacific Canine Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 32: Asia Pacific Canine Vaccines Market Value Share (%), by Route of Administration, 2025
- Figure 33: Asia Pacific Canine Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 34: Asia Pacific Canine Vaccines Market Value Share (%), by Distribution Channel, 2025
- Figure 35: Asia Pacific Canine Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 36: Asia Pacific Canine Vaccines Market Value Share (%), By Country/ Sub-region, 2025
- Figure 37: Latin America Canine Vaccines Market Value (USD billion), by Technology, 2025 & 2034
- Figure 38: Latin America Canine Vaccines Market Value Share (%), by Technology, 2025
- Figure 39: Latin America Canine Vaccines Market Value (USD billion), by Disease Type, 2025 & 2034
- Figure 40: Latin America Canine Vaccines Market Value Share (%), by Disease Type, 2025
- Figure 41: Latin America Canine Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 42: Latin America Canine Vaccines Market Value Share (%), by Route of Administration, 2025
- Figure 43: Latin America Canine Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 44: Latin America Canine Vaccines Market Value Share (%), by Distribution Channel, 2025
- Figure 45: Latin America Canine Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 46: Latin America Canine Vaccines Market Value Share (%), By Country/ Sub-region, 2025
- Figure 47: Middle East & Africa Canine Vaccines Market Value (USD billion), by Technology, 2025 & 2034
- Figure 48: Middle East & Africa Canine Vaccines Market Value Share (%), by Technology, 2025
- Figure 49: Middle East & Africa Canine Vaccines Market Value (USD billion), by Disease Type, 2025 & 2034
- Figure 50: Middle East & Africa Canine Vaccines Market Value Share (%), by Disease Type, 2025
- Figure 51: Middle East & Africa Canine Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 52: Middle East & Africa Canine Vaccines Market Value Share (%), by Route of Administration, 2025
- Figure 53: Middle East & Africa Canine Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 54: Middle East & Africa Canine Vaccines Market Value Share (%), by Distribution Channel, 2025
- Figure 55: Middle East & Africa Canine Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 56: Middle East & Africa Canine Vaccines Market Value Share (%), By Country/ Sub-region, 2025
- Figure 57: Global Canine Vaccines Market Share (%), By Company, 2025
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.